Can Coronary CT Angiography Improve the Prevention of Heart Attacks?

After 10 years, death from coronary heart disease or non-fatal myocardial infarction occurred in:

6.6% of patients whose management included CCTA; 8.2% of patients receiving standard care alone.

The primary outcome therefore occurred less frequently in the CCTA group, with a hazard ratio of 0.79.

The difference was particularly evident for non-fatal myocardial infarction:

4.3% in the CCTA group; 6.0% in the standard-care group.

Major adverse cardiovascular events were also less frequent with CCTA-guided management: 8.3% compared with 10.3%.

Importantly, the improvement in outcomes was not accompanied by an increase in coronary revascularization over the 10-year period. Revascularization occurred in 15.2% of patients in the CCTA group and 15.3% of those receiving standard care alone.

Preventive treatment, however, remained more common among patients whose initial management included CCTA. Among participants with medication data available at 10 years, preventive therapies were prescribed to 55.9% of the CCTA group compared with 49.0% of the standard-care group.

Coronary artery disease develops through the accumulation of atherosclerotic plaque in the coronary arteries, often over many years.

CCTA provides something that a risk calculation alone cannot: direct anatomical information about the coronary arteries.

It can show whether coronary atherosclerosis is present and help determine the extent of coronary artery disease.

This matters because identifying disease can influence what happens next.

Earlier analyses from SCOT-HEART showed that adding CCTA changed the diagnosis of coronary heart disease in approximately one in four patients and led to changes in subsequent investigations and treatment.

The 10-year findings now show that CCTA-guided management was associated with fewer coronary events over the longer term.

For longevity medicine, this illustrates an important principle: diagnostics and prevention are closely connected. Detecting coronary atherosclerosis can provide information that allows preventive management to be better targeted to the individual patient.

CCTA is sometimes thought of primarily as a test for detecting a significant narrowing — or stenosis — in a coronary artery.

Its clinical value is broader.

CCTA can also identify coronary atherosclerosis that is not causing a severe obstruction.

This distinction is clinically important because anatomical imaging and functional stress testing provide different types of information.

A stress test assesses whether coronary disease produces myocardial ischemia during stress. CCTA directly visualizes the coronary arteries and can identify atherosclerotic plaque, including non-obstructive coronary disease that may not produce an abnormal functional test.

A normal functional test therefore does not necessarily mean that coronary atherosclerosis is absent.

In patients with suspected coronary artery disease, anatomical information from CCTA can complement functional assessment by showing whether coronary atherosclerosis is present and how extensive it is.

This distinction helps put the long-term SCOT-HEART findings into clinical context. The improvement in outcomes with CCTA-guided care was not accompanied by more revascularization procedures, while preventive treatment remained more frequent in the CCTA group.

An important value of detecting coronary atherosclerosis may therefore lie not only in identifying patients who require further intervention, but also in identifying disease that can lead to more targeted preventive management.

Finding coronary atherosclerosis does not automatically mean that a patient requires invasive coronary angiography or revascularization. Anatomical findings need to be interpreted together with symptoms, clinical risk, functional evidence of ischemia and the overall clinical picture.

There is also an important limitation.

SCOT-HEART studied patients with stable chest pain and suspected coronary artery disease. It was not a screening trial in healthy, asymptomatic adults.

Its results therefore should not be interpreted as evidence that all asymptomatic people — even those with cardiovascular risk factors — should routinely undergo CCTA. The role of CCTA in selected asymptomatic individuals at elevated cardiovascular risk is a separate clinical question and requires its own evidence base.